Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,553.68
(
-0.42%
)
US TECH 100
23,366.40
(
-0.65%
)
Dow Jones
46,146.34
(
-0.13%
)
Brent Oil
100.91
(
4.25%
)
Bitcoin
69,098.00
(
-2.54%
)
News Focus
News Focus
Post# of 257275
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122807
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: iandy post# 121502

Sunday, 06/12/2011 12:37:21 PM

Sunday, June 12, 2011 12:37:21 PM

Post# of 257275

FCSC—While I believe azficel-T [laViv] has a better than 60% chance of approval, I now agree with Dew that it will have limited if any commercial value. The product had a bad reception the first go round in Europe…it's use will very likely be limited to nasolabial fold wrinkles, and I do not believe the effects are permanent. It was overhyped when first introduced in Europe and there was a big backlash. It is probably being overhyped this time as well.

Amen.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today